Keros Therapeutics, Inc.
KROS
$11.58
$0.110.96%
| Weiss Ratings | KROS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | KROS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | KROS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.23 | |||
| Price History | KROS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -0.77% | |||
| 30-Day Total Return | -1.11% | |||
| 60-Day Total Return | -38.50% | |||
| 90-Day Total Return | -80.05% | |||
| Year to Date Total Return | -27.26% | |||
| 1-Year Total Return | -82.14% | |||
| 2-Year Total Return | -74.35% | |||
| 3-Year Total Return | -76.04% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -84.15% | |||
| 52-Week Low % Change | 17.34% | |||
| Price | KROS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $72.37 | |||
| 52-Week Low Price | $9.78 | |||
| 52-Week Low Price (Date) | Jan 15, 2025 | |||
| 52-Week High Price (Date) | Dec 09, 2024 | |||
| Valuation | KROS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 465.25M | |||
| Enterprise Value | -75.82M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -6.42 | |||
| Earnings Per Share Growth | -1.58% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 130.34 | |||
| Price/Book (Q) | 0.81 | |||
| Enterprise Value/Revenue (TTM) | -21.36 | |||
| Price | $11.58 | |||
| Enterprise Value/EBITDA (TTM) | 0.36 | |||
| Enterprise Value/EBIT | 0.36 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | KROS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 40.34M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | KROS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 314 6297 | |||
| Address | 1050 Waltham Street Lexington, MA 02421 | |||
| Website | www.kerostx.com | |||
| Country | United States | |||
| Year Founded | 2015 | |||
| Profitability | KROS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -5,938.95% | |||
| Profit Margin | -5,277.54% | |||
| Management Effectiveness | KROS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -26.73% | |||
| Return on Equity | -- | |||
| Income Statement | KROS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 3.55M | |||
| Total Revenue (TTM) | 3.55M | |||
| Revenue Per Share | $0.09 | |||
| Gross Profit (TTM) | -14.74M | |||
| EBITDA (TTM) | -209.60M | |||
| EBIT (TTM) | -210.83M | |||
| Net Income (TTM) | -187.35M | |||
| Net Income Avl. to Common (TTM) | -187.35M | |||
| Total Revenue Growth (Q YOY) | 2,027.27% | |||
| Earnings Growth (Q YOY) | -14.37% | |||
| EPS Diluted (TTM) | -6.42 | |||
| EPS Diluted Growth (Q YOY) | 14.58% | |||
| Balance Sheet | KROS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 559.93M | |||
| Cash Per Share (Q) | $13.88 | |||
| Total Current Assets (Q) | 588.89M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 571.55M | |||
| Current Ratio (Q) | 21.453 | |||
| Book Value Per Share (Q) | $14.09 | |||
| Total Assets (Q) | 615.89M | |||
| Total Current Liabilities (Q) | 27.45M | |||
| Total Debt (Q) | 18.86M | |||
| Total Liabilities (Q) | 44.33M | |||
| Total Common Equity (Q) | 571.55M | |||
| Cash Flow | KROS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.93M | |||
| Cash from Financing (TTM) | 391.82M | |||
| Net Change in Cash (TTM) | 229.02M | |||
| Levered Free Cash Flow (TTM) | -108.31M | |||
| Cash from Operations (TTM) | -160.87M | |||
